A supplier statement of “typically ≥99%” by HPLC sounds reassuring, but for a contract research team it should be treated as a prompt for verification, not a proxy for fit-for-purpose release. The figure may tell you something useful about a batch or product family, yet it does not automatically define the method, the sample, the identity check, the contaminant screen or the handling history behind the number. For a materials manager preparing an in-vitro study, the practical question is not simply “is it ≥99%?” but “what exactly has been confirmed, for which batch, and by which document?” Research-use-only materials remain not for human or veterinary use.

Decode the “typically ≥99%” wording before briefing the contract research team

The word typically is doing important work in that sentence. It signals a general expectation rather than a batch-specific specification. Research Sciences states on its site that peptides are typically supplied at ≥99% purity, HPLC tested, with exact purity stated on the CoA. The homepage also lists “≥99% Verified Purity” and “CoAs Janoshik Analytical Reports”; these are published claims to reconfirm on the live site and against the specific batch CoA, not figures to assume for every vial. A contract research team should therefore ask whether the quoted value applies to the exact catalogue item, current batch and analytical method being considered.

“Typically” is not a batch specification. The team should confirm whether the HPLC figure is expressed as area percentage purity, what chromatographic conditions were used, whether identity was confirmed by a separate or complementary method, and whether heavy metals and endotoxin screening are described for the batch in question. Research Sciences describes an expanded testing framework involving heavy metals and endotoxin screening alongside CoA documentation, and its FAQs state that every compound includes a CoA for purity and identity. Those are useful checkpoints, but the researcher still needs to open the actual document rather than rely on a catalogue headline.

Ask the contract research team to separate purity from identity and contaminant screening in their review. A high HPLC purity figure can coexist with questions about sample identity, residual impurities, handling, or the suitability of the material for a particular in-vitro assay. The team should also confirm whether the figure is independent test data, supplier data, or a composite statement, and whether the CoA links to the supplied batch. Any published claim should be reconfirmed on the live page and, where relevant, on the batch CoA. These materials are for controlled laboratory and analytical research only and are not for human or veterinary use.

Confirm batch traceability, CoA details and what the document can—and cannot—prove

Before a study is scheduled, the contract research team should match the vial, label reference, CoA and order record. Research Sciences uses vial label references that combine the SKU code and expiry date, for example BPC10-03/27, and the label should link to the corresponding CoA. The team should quote that reference when contacting the supplier about documentation. A CoA that cannot be tied to the batch in hand is less useful than a clear, traceable record that shows which sample was tested and what was reported.

The team should also review the meaning of any Internal Test Reference, or ITR. Research Sciences’ FAQs note that restocked products may carry the same ITR as earlier stock. An ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colours and other packaging may vary; cap colour is not an indicator of identity, analytical quality or manufacturing origin. These points matter when a materials manager is reconciling several deliveries for one project.

After the intended application and compliance checks are agreed, a materials manager can review the current catalogue through Buy peptides and then open the individual product page for batch-specific CoA guidance. The contract research team should confirm that the CoA covers the fields it actually needs: the analyte, the method, the purity result, the identity check, the contaminant information described by the supplier, and the batch or sample reference. If Janoshik is mentioned, treat it only as the homepage’s published wording—“CoAs Janoshik Analytical Reports”—and check the CoA that accompanies the specific batch rather than assuming a report applies universally.

A documented review should also confirm what the CoA does not establish. It may not prove suitability for a particular assay, stability under a particular reconstitution or storage regime, or freedom from every possible interference. The purchaser remains responsible for lawful use, safe handling, storage and disposal, and for checking that the material is suitable for the intended research application. All products are research-use-only and not for human or veterinary use.

Match handling, storage and fulfilment checks to the in-vitro workflow

The HPLC figure should also prompt a practical conversation about handling. The contract research team should confirm that lyophilised peptides will be stored at –20°C or below, sealed with desiccant, protected from moisture, heat and light, and that repeated freeze–thaw cycles will be avoided. Vials should be allowed to reach room temperature before opening, work should take place in a clean environment, and only the amount required for the experiment should be removed. Reconstituted peptides are less stable and should be stored at 2–8°C for short-term laboratory use.

Where reconstitution is part of an in-vitro laboratory workflow, the team should confirm diluent volume, target concentration for the assay, and compatibility with the planned analytical method. Research Sciences describes a free peptide reconstitution calculator for laboratory research use only; it must not be used for human or veterinary dosing. For catalogue lines such as MT-1 10mg, the product page may describe storage at 2–8°C after reconstitution and note that reconstitution solutions are supplied separately, but those specifics should be checked on the individual product page and batch documentation rather than assumed across the catalogue.

Fulfilment checks belong in the same review. Research Sciences states that orders are dispatched the next working day, shipped via Royal Mail Tracked 24, with tracking after dispatch; delivery times are estimates and may vary in peak periods. The homepage “24hr UK Delivery” line should not be read as a guaranteed next-day arrival. The team should also note that returns are not accepted once dispatched because of the specialist and perishable nature of the goods, with refunds only for damage, incorrect supply or quality issues as set out in the Refunds & Returns Policy.

Finally, the contract research team should confirm that the supplier’s published RUO position aligns with the study’s compliance framework. Research Sciences labels products “For Research Use Only – Not for Human Consumption” and describes this as its stated position in line with MHRA guidance, not as legal advice. The team should verify COSHH and laboratory safety requirements, safe disposal arrangements and internal approval before work begins. A “typically ≥99%” HPLC figure is a useful starting point, but it is the traceable CoA, batch match, handling plan and documented in-vitro suitability review that give the contract research team something it can actually defend. Materials remain not for human or veterinary use.